Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Extravagance SUVs for Seniors: Solace, Innovation, and Security06.06.2024 - 2Figure out How to Pick a Crematorium: Key Contemplations.17.10.2023
- 3Hungary's 'water guardian' farmers fight back against desertification28.12.2025
- 4The most effective method to Offset Album Rates with Liquidity Needs19.10.2023
- 5Figuring out the Justification for Separation: To blame and No-Shortcoming30.06.2023
- 'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- Nature: 10 High priority Setting up camp Spots In Europe
- Independence from the rat race: How to Save and Contribute Shrewdly
- The most effective method to Go with Informed Choices on Vehicle Leases
- Wegmans recalls mixed nuts over salmonella contamination fears
- Wedding Guest Outraged That Bride and Groom, Who Are in Their 60s and Have Both Been Married Before, Registered for Gifts
- If someone's always late, is it time blindness, or are they just being rude?
- What is the 'Survivor 50' Challenge? Hidden immunity idols will be up for grabs in every U.S. state.
- Top Frozen yogurt Flavor: Cast Your Vote!
